A5011622095- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Cutaneous lymphoproliferative disorders research
- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Protein Degradation and Inhibitors
- PI3K/AKT/mTOR signaling in cancer
- CAR-T cell therapy research
- Blood groups and transfusion
- Renal Transplantation Outcomes and Treatments
- Chronic Myeloid Leukemia Treatments
- Immune Cell Function and Interaction
- Hemoglobinopathies and Related Disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Xenotransplantation and immune response
- Histone Deacetylase Inhibitors Research
- Cytomegalovirus and herpesvirus research
- Erythrocyte Function and Pathophysiology
- Cancer Genomics and Diagnostics
- Neutropenia and Cancer Infections
- Viral-associated cancers and disorders
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Childhood Cancer Survivors' Quality of Life
Ospedale Regionale di Bellinzona e Valli
2017-2025
Institute of Oncology Research
2015-2025
Università della Svizzera italiana
2013-2024
Ente Ospedaliero Cantonale
2016-2024
Ospedale San Giovanni Bellinzona
2013-2024
University of Zurich
2005-2023
Swiss Group For Clinical Cancer Research
2023
University Hospital of Bern
2023
Institute Of Perinatology Obstetrics And Gynaecology
2023
Istituto Imaging della Svizzera Italiana
2020
In cancer cells, the epigenome is often deregulated, and inhibition of bromodomain extra-terminal (BET) family bromodomain-containing proteins a novel epigenetic therapeutic approach. Preliminary results an ongoing phase I trial have reported promising activity tolerability with new BET inhibitor OTX015.We assessed preclinical OTX015 as single agent in combination mature B-cell lymphoma models performed vitro vivo experiments to identify mechanism action genetic features associated...
Abstract Purpose: Activation of the PI3K/mTOR signaling pathway is recurrent in different lymphoma types, and pharmacologic inhibition has shown activity patients. Here, we extensively characterized vitro vivo mechanism action PQR309 (bimiralisib), a novel oral selective dual inhibitor under clinical evaluation, preclinical models. Experimental Design: This study included screening on large panel cell lines, both as single agent combination, validation experiments models primary cells,...
Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity. The clinical course variable, multiple genes are mutated with no unifying mechanism, and essential regulatory pathways surrounding microenvironments diverse. We sought to clarify the heterogeneity of SMZL by resolving different subgroups their underlying genomic abnormalities, pathway signatures, microenvironment compositions uncover biomarkers therapeutic vulnerabilities. studied 303 spleen samples...
Patients with severe thrombocytopenia are at risk for bleeding during insertion of central venous catheters (CVCs). Although most guidelines recommend preprocedural platelet (PLT) transfusions a threshold less than 50 × 10(9) /L, there is only weak evidence supporting such recommendations.The current study aimed to establish safe PLT transfusion trigger in patients CVC placements. We performed retrospective single-center analysis 604 insertions 193 acute leukemia receiving intensive...
Traditionally, single-unit red blood cell transfusions were believed to be insufficient treat anemia, but recent data suggest that they may lead a safe reduction of transfusion requirements. We tested this hypothesis by changing from double- policy.We performed retrospective cohort study in patients with hematologic malignancies receiving intensive chemotherapy or hematopoietic stem transplantation. The major end-points the total number units per therapy cycle and day aplasia. comprised 139...
Summary Several methods to detect anti‐A/B antibodies based on haemagglutination and haemolysis have been described. These measure predominantly immunoglobulin (Ig)M, whereas IgG subclasses are less well examined. We established a flow cytometry method (ABO‐fluorescence‐activated cell sorting; ABO‐FACS) quantify binding of IgM, human A or B red blood cells. Anti‐A/B IgM were present in the majority 120 donors, as expected from group typing. The sensitivity specificity predict was 93% 96%...
Background Persistent anti-donor isoagglutinins after major ABO blood group incompatible hematopoietic stem cell transplantation may cause delayed red engraftment and post-transplant pure aplasia.Design Methods We investigated the effect of pretransplant isoagglutinin reduction by in vivo absorption and/or plasmapheresis on incidence aplasia time to 153 transplant recipients with incompatibility.Results Twelve patients (8%) developed aplasia, 3/98 (3%) with, 9/55 (16%) without prior...
Background. Xenoreactive human natural antibodies (NAb) are predominantly directed against galactose-α(1,3)galactose (Gal). Binding of immunoglobulin (Ig) G and IgM NAb activates porcine endothelial cells (pEC) triggers complement lysis responsible for hyperacute xenograft rejection. In vitro, IgG induce killer (NK) cell-mediated pEC by antibody-dependent cytotoxicity (ADCC). The present study examined the levels anti-porcine in a large number individuals addressed functional role non-Gal...
Summary An increased number of circulating monocytes at presentation has recently been associated with shorter survival in Hodgkin lymphoma, follicular lymphoma and diffuse large B cell lymphoma. This study aimed to assess the prognostic impact absolute monocyte count ( AMC ) diagnosis mantle MCL ). was available 97 cases recorded databases Oncology Institute Southern Switzerland Bellinzona (Switzerland) Division Haematology Amedeo Avogadro University Eastern Piedmont Novara (Italy). With a...
Antibody-drug conjugates (ADC) are a novel way to deliver potent cytotoxic compounds cells expressing specific antigen. Four ADC targeting CD19, including SAR3419 (coltuximab ravtansine), have entered clinical development. Here, we present huB4-DGN462, based on the anti-CD19 antibody linked via sulfo-SPDB DNA-alkylating agent DGN462. huB4-DGN462 had improved in vitro anti-proliferative and activity compared across multiple B-cell lymphoma human acute lymphoblastic leukemia cell lines. In...
Antibody drug conjugates represent an important class of anti-cancer drugs in both solid tumors and hematological cancers. Here, we report preclinical data on the anti-tumor activity first-in-class antibody conjugate MEN1309/OBT076 targeting CD205. The study included vitro screening a large panel cell lines, as single agent combination validation experiments vivo models. CD205 was first shown frequently expressed lymphomas, leukemias multiple myeloma by immunohistochemistry tissue...
The rationale for combining ibrutinib and venetoclax (IV) in chronic lymphocytic leukemia (CLL) treatment lies their complementary mechanisms of action. Studies investigating IV typically begin with a short initial course ibrutinib, followed by introduction limited duration, 12 months. SAKK34/17 (NCT03708003) is single-arm, open-label, multicenter, phase 2 trial evaluating the effectiveness modified schedule patients relapsed/refractory (R/R) CLL. No prior exposure to BTK- or BCL2-inhibitors...